Back

Efficacy and safety of HERG channel agonists for treatment of Long QT Syndrome type 8

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Novel insights into arrhythmias Arrhythmias ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Deni Kukavica

ICS Maugeri - IRCCS Pavia, Pavia (Italy)

8 More presentations in this session

Presentation thumbnail
Characterisation of the novel SCN5A-P1891A variant, implicated in left ventricular noncompaction cardiomyopathy in a Finnish family, using human induced pluripotent stem cell-derived cardiomyocytes.
Doctor Q. Majid (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Advancing cardiac 3D organoid-on-chip: integrating iPSC-derived MELAS syndrome models to study electromechanical synchronicity and cardiac memory using contactless technology
Associate Professor M. Miragoli (Parma, IT)
Abstract Slides Video
Presentation thumbnail
Investigating the role of WT1 in Brugada syndrome pathophysiology
Ms M. Marsman (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Computational modeling of cardiac electrophysiology applied to a swine model of Long QT Syndrome
Doctor A. Trancuccio (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Indoxyl sulfate deteriorates cardiac electrophysiological function and increases the likelihood of arrhythmias in human ventricular myocardial cells
Mr O. Pfeuffer (Regensburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insights into arrhythmias

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Computational modeling of cardiac electrophysiology applied to a swine model of Long QT Syndrome
thumbnail
Congress Presentation
In vivo KCNQ1-suppression-replacement gene therapy in transgenic LQT1 rabbits restores a physiological QT interval at baseline and under catecholamine infusion
thumbnail
Congress Presentation
Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources